Dermatology · Urticarial Vasculitis

Subtypes of Urticarial Vasculitis: Classifying Your Condition

At a Glance

Urticarial vasculitis is classified by complement levels and whether disease is limited to the skin or affects organs. Low complement suggests HUV, but anti-C1q results, SLE features, symptoms, and changes over time also guide classification and monitoring.

Understanding where you fit into the spectrum of Urticarial Vasculitis (UV) is an important step in managing your health. Because this condition ranges from skin-only issues to a complex systemic disease, doctors use clinical classifications to guide your monitoring and treatment ^[1]^[2].

The First Branch: Complement Status

The most basic way doctors categorize UV is by measuring complement proteins (C1q, C3, and C4) in your blood. These proteins are part of your immune system’s cleanup crew ^[3].

Normocomplementemic Urticarial Vasculitis (NUV): Your complement levels are in the normal range. While still a serious vasculitis, NUV is generally less likely to involve internal organs than the hypocomplementemic form ^[1]^[2].
Hypocomplementemic Urticarial Vasculitis (HUV): Your complement levels are low. This indicates that your immune system is consuming these proteins. HUV is more strongly linked to systemic (body-wide) involvement ^[2]^[4].

The 2012 Chapel Hill Nomenclature: “Anti-C1q Vasculitis”

You may see the term Anti-C1q Vasculitis in your medical records. This is a classification designated by the 2012 International Chapel Hill Consensus Conference (CHCC) to describe a vasculitis associated with anti-C1q autoantibodies ^[5].

Not a Universal Synonym: It is important to know that this term describes a specific associated finding. It should not be used as a blanket synonym for every case of HUV or HUVS, especially in patients whose anti-C1q testing is negative ^[6].
The C1q Marker: A low C1q level may also be present, but neither finding perfectly defines every presentation of the disease ^[6].

Clinical Classifications: From Skin-Limited to Systemic

Once HUV is identified, doctors evaluate how it affects your body to classify the disease:

Classification	Description	Focus of Care
Skin-Limited HUV	Vasculitis is found only in the skin; complement is low, but no other organs are currently affected ^[7].	Focus on skin comfort and individualized monitoring to catch potential systemic signs.
Systemic HUVS (McDuffie Syndrome)	HUV is present along with systemic manifestations and/or accepted clinical criteria (such as joint, eye, lung, or kidney involvement) ^[8]^[9].	Intensive monitoring and treatment to protect vital organ function (especially lungs and kidneys).
SLE-Associated HUV	The patient’s clinical picture and laboratory findings meet the full criteria for both HUV and Systemic Lupus Erythematosus (SLE) ^[9]^[10].	Coordination between dermatology and rheumatology to manage the overlap of both conditions.

Rare Pediatric and Familial Cases: The DNASE1L3 Link

In very specific situations—such as early-onset disease in children or families where multiple people have HUV or Lupus—a rare genetic factor may be considered. Variants in the DNASE1L3 gene are a rare cause of monogenic lupus and vasculitis-spectrum disease ^[11]^[12].

Targeted Testing: This is not a routine explanation for HUVS. Genetic testing is considered selectively by a clinical geneticist when the age of onset, family history, or specific severe phenotype warrants it ^[13]^[14].
Spectrum of Disease: The same genetic variant can lead to HUV, SLE, or a mix of both in different patients ^[11].

A Note on Progression

These categories are not always permanent. Someone may start with skin-limited HUV but develop joint or kidney symptoms months or even years later ^[15]^[16]. This is why your medical team will likely establish an individualized, long-term monitoring plan, even if your skin looks clear ^[17]^[12].

Common questions in this guide

What do low complement levels mean in urticarial vasculitis?

Low levels of complement proteins such as C1q, C3, and C4 place the condition in the hypocomplementemic urticarial vasculitis, or HUV, category. HUV is more strongly associated with involvement beyond the skin than normocomplementemic urticarial vasculitis, although complement results do not by themselves describe every part of a person’s disease.

Is anti-C1q vasculitis another name for HUV?

Not always. Anti-C1q vasculitis refers to a classification associated with anti-C1q autoantibodies, while HUV is defined by low complement levels; anti-C1q testing can be negative in some people with HUV or HUVS. A low C1q level may also be present, but neither result alone captures every presentation.

What is systemic HUVS or McDuffie syndrome?

Systemic HUVS, also called McDuffie syndrome, means HUV occurs with systemic manifestations or accepted clinical criteria. Findings may involve the joints, eyes, lungs, or kidneys, so doctors monitor organ function and tailor treatment.

How is HUV related to systemic lupus erythematosus?

SLE-associated HUV is considered when a person meets clinical and laboratory criteria for both hypocomplementemic urticarial vasculitis and systemic lupus erythematosus. Doctors may review lupus-related findings and monitor markers such as anti-dsDNA and anti-Sm as part of that evaluation.

Can skin-limited HUV become systemic later?

Yes. A person may initially have vasculitis limited to the skin and later develop joint, eye, lung, or kidney involvement months or years afterward. This is why clinicians may recommend individualized, long-term monitoring even when skin symptoms improve.

When might genetic testing for DNASE1L3 be considered?

Testing is considered selectively when disease begins early, several family members have HUV or lupus, or the clinical picture is unusually severe. A clinical geneticist can help decide whether testing for DNASE1L3-related disease is appropriate; it is not a routine explanation for HUVS.

Curated prompts to bring to your next appointment.

1.Given my complement levels and systemic symptoms, which classification best describes my condition?
2.What specific organ findings (like in my lungs or kidneys) led to my current clinical classification?
3.Are my anti-C1q antibodies positive, and if not, does my low C1q level still influence my overall diagnosis?
4.How do you distinguish my condition from SLE, and are there specific markers like anti-dsDNA or anti-Sm that we are monitoring?
5.Given the severity or early age of onset of my symptoms, should we consider consultation with a clinical geneticist regarding DNASE1L3 deficiency?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (17)

1
Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis.
Marzano AV, Maronese CA, Genovese G, et al.
The Journal of allergy and clinical immunology 2022; (149(4)):1137-1149 doi:10.1016/j.jaci.2022.02.007.
PMID: 35396080
2
Correct approach in urticarial vasculitis made early diagnosis of lupus nephritis possible: a case report.
Smets K, Van Baelen A, Sprangers B, De Haes P
Journal of medical case reports 2022; (16(1)):314 doi:10.1186/s13256-022-03477-6.
PMID: 35989318
3
Case Report: Hypocomplementemic urticarial vasculitis syndrome in a pediatric patient with complement factor 1 deficiency.
Lin S, Kafisheh D, Elder ME
Frontiers in pediatrics 2024; (12()):1448094 doi:10.3389/fped.2024.1448094.
PMID: 39376673
4
Clinical Profile of Patients with Urticarial Vasculitis in China: A Retrospective of 142 Cases.
Hu W, Zhu Y, Geng S, et al.
Journal of inflammation research 2026; (19()):576374 doi:10.2147/JIR.S576374.
PMID: 41877830
5
An update on the nomenclature for cutaneous vasculitis.
Caproni M, Verdelli A
Current opinion in rheumatology 2019; (31(1)):46-52 doi:10.1097/BOR.0000000000000563.
PMID: 30394939
6
[Hypocomplementemic urticarial vasculitis].
Jachiet M, Flageul B, Bouaziz JD, et al.
La Revue de medecine interne 2018; (39(2)):90-98 doi:10.1016/j.revmed.2017.03.005.
PMID: 28457680
7
Urticarial vasculitis and urticarial autoinflammatory syndromes.
Marzano AV, Tavecchio S, Venturini M, et al.
Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2015; (150(1)):41-50.
PMID: 25586657
8
Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis).
Sjöwall C, Mandl T, Skattum L, et al.
Rheumatology (Oxford, England) 2018; (57(8)):1400-1407 doi:10.1093/rheumatology/key110.
PMID: 29718374
9
Urticarial hypocomplementemic vasculitis syndrome and systemic lupus erythematosus: a case report and review of the literature.
Ouerdani Y, Ben Achour T, Ben Hmid A, et al.
Frontiers in immunology 2025; (16()):1649699 doi:10.3389/fimmu.2025.1649699.
PMID: 40852710
10
Dermal C4d Deposition and Neutrophil Alignment Along the Dermal-Epidermal Junction as a Diagnostic Adjunct for Hypocomplementemic Urticarial Vasculitis (Anti-C1q Vasculitis) and Underlying Systemic Disease.
Damman J, Mooyaart AL, Seelen MAJ, van Doorn MBA
The American Journal of dermatopathology 2020; (42(6)):399-406 doi:10.1097/DAD.0000000000001501.
PMID: 31436578
11
Unraveling the Clinical Spectrum of DNASE1L3 Deficiency: Insights from Case Series and Systematic Literature Review.
Ercan Emreol H, Unal D, Sag E, et al.
Current rheumatology reports 2026; (28(1)).
PMID: 42726335
12
Discordance between disease activity and long-term outcomes in DNASE1L3 deficiency: a multicentre longitudinal cohort study.
Abdwani R, Al Abrawi S, Aljaberi N, et al.
Lupus science & medicine 2026; (13(2)) doi:10.1136/lupus-2026-002175.
PMID: 42716676
13
Childhood-onset hypocomplementaemic urticarial vasculitis in France: phenotypic and genotypic diversity in 10 children.
Bianchi C, Melki I, Sisirak V, et al.
Pediatric rheumatology online journal 2026; (24(1)).
PMID: 41807955
14
DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling.
Tusseau M, Lovšin E, Samaille C, et al.
Journal of clinical immunology 2022; (42(6)):1310-1320 doi:10.1007/s10875-022-01287-5.
PMID: 35670985
15
Hypocomplementemic Urticarial Vasculitis Syndrome with Membranous Nephropathy: Case Report.
Jung SW, Choi YY, Choi IS, et al.
Journal of Korean medical science 2017; (32(12)):2064-2068 doi:10.3346/jkms.2017.32.12.2064.
PMID: 29115092
16
Hypocomplementemic Urticarial Vasculitis Syndrome or Systemic Lupus Erythematosus in Evolution?
Kesarwani V, Phachu D, Trivedi R
Cureus 2022; (14(3)):e23429 doi:10.7759/cureus.23429.
PMID: 35481300
17
Hypocomplementemic Urticarial Vasculitis Syndrome: A Rare Form of Vasculitis.
Singh SK, Gupta M, Rani S, Singh P
Cureus 2025; (17(1)):e78227 doi:10.7759/cureus.78227.
PMID: 40026936

This page explains how clinicians classify urticarial vasculitis and HUV for education; it cannot determine your diagnosis or replace advice from your dermatologist, rheumatologist, or other healthcare professional.

Get notified when new evidence is published on Hypocomplementemic urticarial vasculitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents